1174 / 1816
Recommendations endocrine therapy
Postmenopausal
women
• A minimum of 5 years of adjuvant therapy using either an AI or a sequence
of tamoxifen followed by an AI.
• Women who are postmenopausal who receive tamoxifen as initial
treatment are candidates for extended adjuvant endocrine treatment
either by continuing tamoxifen for a total of 10 years, or by
switching to an AI.
• As there are no data for the efficacy or safety of AI therapy in excess of 5
years, 5 years remains the appropriate duration of AI treatment, whether
begun as initial therapy or after prior tamoxifen.
Caution against longer durations of treatment when neither safety nor efficacy
data were available.
19-9-2017
ASCO guideline